查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571659

免疫毒素市場規模、佔有率和趨勢分析報告：2024-2030 年按產品、應用、最終用途、地區和細分市場進行的預測

Immunotoxins Market Size, Share & Trends Analysis Report By Product (Pseudomonas Exotoxin), By Application (Therapy Development), By End-use (Pharmaceutical & Biotechnology Companies),By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

免疫毒素市場成長與趨勢：

根據Grand View Research, Inc.的最新報告，預計到2030年，全球免疫毒素市場將達到2.433億美元，2024年至2030年複合年成長率為8.08%。

癌症盛行率上升和技術進步是預計推動市場成長的一些因素。

免疫毒素是一種標靶治療，將細胞毒性藥物與抗體或生長因子等標靶部分結合。由於免疫毒素在治療多種癌症和其他疾病方面的潛力，其發展勢頭強勁。癌症在全世界日益受到關注，預計到 2022 年將有 2,000 萬新發病例和 970 萬人死亡。免疫毒素由與毒素連接的抗體片段或標靶部分組成，可以選擇性地將有毒物質直接遞送至癌細胞。此外，免疫毒素的開發和應用在最近的趨勢中取得了顯著進展，並且正在進行各種研究舉措，旨在提高其功效、降低免疫抗原性並擴大其治療應用。研究人員正在鑑定新的腫瘤特異性抗原，這些抗原可以作為新的免疫毒素療法的標靶。

COVID-19 大流行對全球供應鏈造成了重大破壞。由於衛生法規和勞動力短缺，製造設施面臨關閉或營運減少。這種情況影響了生產免疫毒素所需的原料和成分的可用性。此外，疫情促進了製藥公司、學術機構和政府機構之間的合作，並加快了藥物開發進程，進一步促進了市場成長。

然而，與免疫毒素治療相關的主要挑戰之一是潛在的嚴重副作用。患者可能會出現噁心、腹瀉和發燒等副作用。例如，某些毒素，例如基於蓖麻毒素的免疫毒素，與嚴重的併發症例如毛細血管滲漏症候群和肝毒性有關。這些風險可能導致臨床試驗暫停和醫藥品認證過程中的監管障礙，進一步限制市場成長。

免疫毒素市場報告亮點

  • 按產品分類，白喉毒素（DT）細分市場在2023年佔據最大市場佔有率，為43.96%。基於 DT 的免疫毒素在針對特定癌細胞方面非常有效，這使得它們對於治療對化療和放射線治療等標準療法抗藥性的癌症很有價值。同時，假單胞菌外毒素（PE）預計在預測期內將以顯著的複合年成長率成長。
  • 按應用分類，治療開發領域預計將在 2023 年佔據按應用分類的市場佔有率，並在預測期內以最快的複合年成長率成長。
  • 按最終用途分類，製藥和生技公司在 2023 年佔據最大佔有率，為 46.40%，預計在預測期內將以最快的複合年成長率成長。但另一方面，學術機構預計在預測期內將以顯著的複合年成長率成長。
  • 從地區來看，北美以 41.41% 的佔有率佔據市場主導地位。這是由於生物技術、醫學和治療學方面的強大研究和發展以及政府的大量資助等因素。預計亞太地區在預測期內將以最快的複合年成長率成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章免疫毒素市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望。
  • 市場動態
    • 市場成長要素分析
    • 市場限制因素分析
  • 免疫毒素市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章 免疫毒素市場：依產品估算與趨勢分析

  • 細分儀表板
  • 全球免疫毒素市場波動分析：按產品
  • 全球免疫毒素市場規模及趨勢分析：依產品分類，2018-2030年
  • 白喉毒素 (DT)
  • 炭疽菌毒素
  • 假單胞菌外毒素 (PE)
  • 其他免疫毒素

第5章免疫毒素市場：按應用估算和趨勢分析

  • 細分儀表板
  • 全球免疫毒素市場波動分析：按應用
  • 全球免疫毒素市場規模及趨勢分析：依應用分類，2018-2030
  • 生物調查
  • 治療開發

第6章免疫毒素市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 全球免疫毒素市場波動分析：依最終用途分類
  • 全球免疫毒素市場規模與趨勢分析：依最終用途分類，2018-2030
  • 製藥和生物技術公司
  • 合約研究官（CRO）和首席行銷長（CMO）
  • 學術研究所

第7章免疫毒素市場：按地區估算及趨勢分析

  • 市場佔有率分析：按地區分類，2023 年和 2030 年
  • 市場儀表板：按地區
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 公司/競爭對手分類
  • 策略規劃
  • 2023 年企業市場分析
  • 公司簡介/上市公司
    • Creative Biolabs.
    • List Biological Labs, Inc.
    • The Native Antigen Company
    • Bio-Techne.
    • Abcam Plc.
    • CAYMAN CHEMICAL
    • Merck KGaA
    • Enzo Life Sciences, Inc.
    • Santa Cruz Biotechnology, Inc.
    • Quadratech Diagnostics Ltd.
Product Code: GVR-4-68040-464-4

Immunotoxins Market Growth & Trends:

The global immunotoxins market is anticipated to reach USD 243.3 million by 2030 and is anticipated to expand at a CAGR of 8.08% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of cancer and technological advancements are some of the factors anticipated to drive market growth.

Immunotoxins are a class of targeted therapeutics that combine a cytotoxic agent with a targeting moiety, such as an antibody or growth factor. The development of immunotoxins has gained momentum due to their potential effectiveness in treating various cancers and other diseases. Cancer is a growing concern worldwide, with an estimated 20 million new cases and 9.7 million deaths in 2022. Immunotoxins consist of an antibody fragment, or a targeting moiety linked to a toxin, which allows for selective delivery of the toxic agent directly to cancer cells. Moreover, the development and application of immunotoxins have evolved significantly over recent years, leading to various ongoing research initiatives aimed at improving their efficacy, reducing immunogenicity, and expanding their therapeutic applications. Researchers are identifying novel tumor-specific antigens that could serve as targets for new immunotoxin therapies.

The COVID-19 pandemic led to significant disruptions in global supply chains. Manufacturing facilities faced shutdowns or reduced operations due to health regulations and workforce shortages. This situation affected the availability of raw materials and components necessary for producing immunotoxins. Moreover, the pandemic fostered collaboration among pharmaceutical companies, academic institutions, and government entities to accelerate drug development processes, further propelling market growth.

However, one of the primary challenges associated with immunotoxin therapies is the potential for severe side effects. Patients may experience adverse reactions such as nausea, diarrhea, and fever. For instance, certain toxins like Ricin-based immunotoxins have been associated with severe complications such as capillary leak syndrome or hepatotoxicity. Such risks can lead to clinical trial terminations or regulatory hurdles during drug approval processes, further limiting market growth.

Immunotoxins Market Report Highlights:

  • Based on product, the Diphtheria Toxin (DT) segment held the largest market share of 43.96% in 2023. DT-based immunotoxins are highly effective in targeting specific cancer cells, making them valuable for treating cancers that are resistant to standard therapies like chemotherapy and radiation. On the other hand, Pseudomonas Exotoxin (PE) is anticipated to grow at a significant CAGR over the forecast period.
  • Based on application, in 2023, therapy development segment is anticipated to dominate the market share for the application segment and is anticipated to grow at the fastest CAGR over the forecast period.
  • Based on end-use, pharmaceutical & biotechnology companies segment dominated the end use segment with the largest share of 46.40% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period. However, on the other hand, academic institutes is anticipated to grow at a significant CAGR over the forecast period.
  • Based on region, North America region dominated the market with a share of 41.41% owing to factors such as strong R&D in biotechnology, medicine, and therapeutics, along with substantial government funding. Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Application Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. Immunotoxins Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of cancer
      • 3.2.1.2. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Cytotoxic and manufacturing challenges associated with immunotoxins
  • 3.3. Immunotoxins Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Immunotoxins Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Immunotoxins Market Product Movement Analysis
  • 4.3. Global Immunotoxins Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Diphtheria Toxin (DT)
    • 4.4.1. Diphtheria toxin (DT) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Anthrax Based Toxins
    • 4.5.1. Anthrax based toxins market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Pseudomonas Exotoxin (PE)
    • 4.6.1. Pseudomonas exotoxin (PE) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Other Immunotoxins
    • 4.7.1. Other immunotoxins market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Immunotoxins Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Immunotoxins Market Application Movement Analysis
  • 5.3. Global Immunotoxins Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Biomedical Research
    • 5.4.1. Biomedical research market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Therapy Development
    • 5.5.1. Therapy development market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Immunotoxins Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Immunotoxins Market End Use Movement Analysis
  • 6.3. Global Immunotoxins Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biotechnology Companies
    • 6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. CROs & CMOs
    • 6.5.1. CROs & CMOs market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Academic & Research Institutes
    • 6.6.1. Academic & research institutes market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Immunotoxins Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Competitive scenario
      • 7.4.1.3. Regulatory framework
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. Creative Biolabs.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. List Biological Labs, Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. The Native Antigen Company
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Bio-Techne.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Abcam Plc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. CAYMAN CHEMICAL
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Merck KGaA
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Enzo Life Sciences, Inc.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Santa Cruz Biotechnology, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Quadratech Diagnostics Ltd.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global immunotoxins market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 4 Global immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 9 North America immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 11 U.S. immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 12 U.S. immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 14 Canada immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Mexico immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 17 Mexico immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 21 Europe immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Germany immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 24 Germany immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 25 Germany immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 26 UK immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 27 UK immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 28 UK immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 29 France immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 30 France immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 31 France immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Italy immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 33 Italy immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Spain immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 36 Spain immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 37 Spain immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Denmark immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 39 Denmark immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 40 Denmark immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Sweden immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 42 Sweden immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 43 Sweden immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Norway immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 45 Norway immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 46 Norway immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 51 China immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 52 China immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 53 China immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Japan immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 55 Japan immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 56 Japan immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 57 India immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 58 India immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 59 India immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 60 South Korea immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 61 South Korea immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 62 South Korea immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 63 Australia immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 64 Australia immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 65 Australia immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Thailand immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 67 Thailand immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 68 Thailand immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Latin America immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 71 Latin America immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 72 Latin America immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Brazil immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 74 Brazil immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 75 Brazil immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 76 Argentina immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 77 Argentina immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 78 Argentina immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 79 MEA immunotoxins market, by country, 2018 - 2030 (USD Million)
  • Table 80 MEA immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 81 MEA immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 82 MEA immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 83 South Africa immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 84 South Africa immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Africa immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 89 UAE immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 90 UAE immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 91 UAE immunotoxins market, by end use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait immunotoxins market, by product, 2018 - 2030 (USD Million)
  • Table 93 Kuwait immunotoxins market, by application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait immunotoxins market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Immunotoxins market: Market outlook
  • Fig. 5 Immunotoxins market: Segment outlook
  • Fig. 6 Immunotoxins market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Immunotoxins market driver impact
  • Fig. 9 Immunotoxins market restraint impact
  • Fig. 10 Immunotoxins market: Product outlook and key takeaways
  • Fig. 11 Immunotoxins market: Product movement analysis
  • Fig. 12 Diphtheria toxin (DT) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Anthrax based toxins market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Pseudomonas exotoxin (PE) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Other immunotoxins market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Immunotoxins market: Application outlook and key takeaways
  • Fig. 17 Immunotoxins market: Application movement analysis
  • Fig. 18 Biomedical research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Therapy development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Immunotoxins market: End Use outlook and key takeaways
  • Fig. 21 Immunotoxins market: End Use movement analysis
  • Fig. 22 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 23 CROs & CMOs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Global immunotoxins market: Regional outlook and key takeaways
  • Fig. 26 Global immunotoxins market: Regional movement analysis
  • Fig. 27 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Key country dynamics
  • Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Key country dynamics
  • Fig. 31 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Key country dynamics
  • Fig. 33 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Key country dynamics
  • Fig. 36 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Key country dynamics
  • Fig. 44 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)